Review anchor
MC9
CELL-LINE · Mus musculus
As of 2026-09-14
Evidence Snapshot
MC9
CHEMBL614867
CELL-LINE
Mus musculus
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats MC9 as ChEMBL target CHEMBL614867. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL614867
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-14
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-14
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why MC9 matters
MC9 is reviewed as MC9; the current evidence base includes 3 approved drugs, 30 compounds, and 38 assays, with lead potency reaching pChEMBL 8.2.
Protein context
MC9
MC9
Review this target as MC9.
Protein source · UniProt accession via ChEMBL component mappingDisease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 3 approved drugs, 30 compounds, and 38 assays for this target. The dominant activity type is IC50. CHEMBL404529 is the current potency anchor at pChEMBL 8.2.
Use CHEMBL404529 as the tractability anchor when discussing potency (pChEMBL 8.2).
Activity source · ChEMBL 36 via Core Engine
3 approved
pChEMBL 8.2
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why MC9 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
30
Total Compounds
38
Total Assays
3
Approved Drugs
IC50: 18.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL404529
|
8.2 | IC50 | — |
|
|
No preferred name
CHEMBL269787
|
7.7 | IC50 | Clinical |
|
|
No preferred name
CHEMBL272342
|
7.7 | IC50 | Clinical |
|
|
No preferred name
CHEMBL154
|
6.7 | IC50 | Approved |
|
|
No preferred name
CHEMBL118
|
6.5 | IC50 | Approved |
Approved Drugs
Source Header